JP2025108645A5 - - Google Patents

Info

Publication number
JP2025108645A5
JP2025108645A5 JP2025069088A JP2025069088A JP2025108645A5 JP 2025108645 A5 JP2025108645 A5 JP 2025108645A5 JP 2025069088 A JP2025069088 A JP 2025069088A JP 2025069088 A JP2025069088 A JP 2025069088A JP 2025108645 A5 JP2025108645 A5 JP 2025108645A5
Authority
JP
Japan
Prior art keywords
hsv
infection
immunogenic fragment
rna encoding
glycoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025069088A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025108645A (ja
Filing date
Publication date
Priority claimed from PCT/IB2018/056210 external-priority patent/WO2019035066A1/en
Application filed filed Critical
Publication of JP2025108645A publication Critical patent/JP2025108645A/ja
Publication of JP2025108645A5 publication Critical patent/JP2025108645A5/ja
Pending legal-status Critical Current

Links

JP2025069088A 2017-08-17 2025-04-18 単純ヘルペスウイルス糖タンパク質をコードする修飾mRNAワクチン及びその使用 Pending JP2025108645A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762546648P 2017-08-17 2017-08-17
US62/546,648 2017-08-17
US201862701019P 2018-07-20 2018-07-20
US62/701,019 2018-07-20
PCT/IB2018/056210 WO2019035066A1 (en) 2017-08-17 2018-08-17 MODIFIED MHRNA VACCINES ENCODING HERPES SIMPLEX VIRUS GLYCOPROTEINS AND USES THEREOF
JP2020509054A JP7386535B2 (ja) 2017-08-17 2018-08-17 単純ヘルペスウイルス糖タンパク質をコードする修飾mRNAワクチン及びその使用
JP2023138084A JP7674760B2 (ja) 2017-08-17 2023-08-28 単純ヘルペスウイルス糖タンパク質をコードする修飾mRNAワクチン及びその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023138084A Division JP7674760B2 (ja) 2017-08-17 2023-08-28 単純ヘルペスウイルス糖タンパク質をコードする修飾mRNAワクチン及びその使用

Publications (2)

Publication Number Publication Date
JP2025108645A JP2025108645A (ja) 2025-07-23
JP2025108645A5 true JP2025108645A5 (enExample) 2026-02-26

Family

ID=65362983

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020509054A Active JP7386535B2 (ja) 2017-08-17 2018-08-17 単純ヘルペスウイルス糖タンパク質をコードする修飾mRNAワクチン及びその使用
JP2023138084A Active JP7674760B2 (ja) 2017-08-17 2023-08-28 単純ヘルペスウイルス糖タンパク質をコードする修飾mRNAワクチン及びその使用
JP2025069088A Pending JP2025108645A (ja) 2017-08-17 2025-04-18 単純ヘルペスウイルス糖タンパク質をコードする修飾mRNAワクチン及びその使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2020509054A Active JP7386535B2 (ja) 2017-08-17 2018-08-17 単純ヘルペスウイルス糖タンパク質をコードする修飾mRNAワクチン及びその使用
JP2023138084A Active JP7674760B2 (ja) 2017-08-17 2023-08-28 単純ヘルペスウイルス糖タンパク質をコードする修飾mRNAワクチン及びその使用

Country Status (7)

Country Link
US (3) US11141478B2 (enExample)
EP (2) EP4242223A3 (enExample)
JP (3) JP7386535B2 (enExample)
CN (2) CN111246854A (enExample)
AU (2) AU2018316811B2 (enExample)
CA (1) CA3073161A1 (enExample)
WO (1) WO2019035066A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200054737A1 (en) * 2017-04-26 2020-02-20 Modema TX, Inc. Herpes simplex virus vaccine
AU2018316811B2 (en) 2017-08-17 2023-07-13 The Trustees Of The University Of Pennsylvania Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof
AU2020233995A1 (en) * 2019-03-12 2021-09-23 BioNTech SE Therapeutic RNA for prostate cancer
CN111568856B (zh) * 2020-06-24 2021-07-06 珠海舒桐医疗科技有限公司 一种阴道凝胶制剂及其制备方法
WO2022002783A1 (en) * 2020-06-29 2022-01-06 Glaxosmithkline Biologicals Sa Adjuvants
US12419948B2 (en) 2020-08-31 2025-09-23 The Broad Institute, Inc. Immunogenic compositions and use thereof
EP4225360A1 (en) 2020-10-08 2023-08-16 Virothera Limited Vaccine compositions
EP4032547A1 (en) * 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Hsv1 fce derived fragements for the treatment of hsv
EP4032546A1 (en) * 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Therapeutic viral vaccine
EP4284335A1 (en) 2021-02-01 2023-12-06 RegenxBio Inc. Gene therapy for neuronal ceroid lipofuscinoses
CA3211277A1 (en) 2021-03-11 2022-09-15 Marina TAMBASCO STUDART Vaccine compositions and methods for treating hsv
CN118217388A (zh) * 2022-12-19 2024-06-21 南京奥罗生物科技有限公司 单纯疱疹病毒疫苗及其应用
TW202434263A (zh) * 2023-01-27 2024-09-01 德商拜恩技術股份公司 用於遞送單純疱疹病毒醣蛋白c、醣蛋白d、及醣蛋白e抗原之醫藥組成物及相關方法
WO2024163918A1 (en) * 2023-02-02 2024-08-08 University Of Houston System Mrna vaccine for herpes simplex virus
WO2024249967A1 (en) * 2023-06-02 2024-12-05 The Trustees Of The University Of Pennsylvania Rna vaccines encoding herpes simplex virus glycoproteins and uses thereof
WO2025030165A1 (en) * 2023-08-03 2025-02-06 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
AU2024318951A1 (en) 2023-08-03 2026-03-12 BioNTech SE Rna compositions encoding herpes simplex virus glycoprotein e and/or glycoprotein i antigens and uses thereof
AU2024316307A1 (en) * 2023-08-03 2026-02-26 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
AU2024316992A1 (en) 2023-08-03 2026-03-12 BioNTech SE Rna compositions encoding herpes simplex virus glycoprotein b antigens and uses thereof
WO2025072383A1 (en) 2023-09-25 2025-04-03 The Broad Institute, Inc. Viral open reading frames, uses thereof, and methods of detecting the same
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025109008A1 (en) 2023-11-20 2025-05-30 Redbiotec Ag Novel vaccine compositions and methods for treating hsv
WO2025129158A1 (en) 2023-12-15 2025-06-19 The Broad Institute, Inc. Engineered arc delivery vesicles and uses thereof
WO2025175124A1 (en) * 2024-02-15 2025-08-21 Albert Einstein College Of Medicine Recombinant herpes simplex virus glycoprotein b for treatment and prevention of herpes simplex virus infections
WO2025212831A1 (en) * 2024-04-03 2025-10-09 The Trustees Of The University Of Pennsylvania Methods of inducing an anti-hsv b-cell immune response

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
RS63964B1 (sr) 2005-08-23 2023-03-31 Univ Pennsylvania Rnk koja sadrži modifikovane nukleozide i postupci za njenu upotrebu
EP2521786B1 (en) 2006-07-20 2015-06-24 Vical Incorporated Compositions for vaccinating against hsv-2
US20130028925A1 (en) 2006-12-28 2013-01-31 Harvey Friedman Herpes simplex virus combined subunit vaccines and methods of use thereof
US9284355B2 (en) * 2006-12-28 2016-03-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
AU2010249330B2 (en) * 2009-05-22 2015-11-05 Genocea Biosciences Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
EP2496700B1 (en) 2009-11-04 2017-03-01 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
US9192661B2 (en) * 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
US9770463B2 (en) * 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
SI2850431T1 (en) * 2012-05-16 2018-08-31 Immune Design Corp. Vaccines for hsv-2
WO2015089340A1 (en) * 2013-12-11 2015-06-18 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Human herpesvirus trimeric glycoprotein b, protein complexes comprising trimeric gb and their use as vaccines
DK3142750T3 (da) * 2014-05-13 2020-09-14 Univ Pennsylvania Sammensætninger omfattende aav, som udtrykker dobbelt-antistofkonstrukter og anvendelser deraf
CA2962639A1 (en) * 2014-10-01 2016-04-07 Jingang Medicine (Australia) Pty Ltd Therapeutic compositions and methods for inducing an immune response to herpes simplex virus type 2 (hsv-2)
EP3289083A4 (en) 2015-04-27 2018-12-19 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
US10758694B2 (en) 2015-07-09 2020-09-01 Hoyt Medical LLC Systems and methods for treating an airway using a tapered adapter device
BR112018008090A2 (pt) 2015-10-22 2018-11-13 Modernatx Inc vacina de vírus do herpes simplex.
CA3002819A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Sexually transmitted disease vaccines
IL317855A (en) * 2016-10-26 2025-02-01 Acuitas Therapeutics Inc mRNA vaccines with lipid nanoparticles
US20200054737A1 (en) 2017-04-26 2020-02-20 Modema TX, Inc. Herpes simplex virus vaccine
AU2018316811B2 (en) 2017-08-17 2023-07-13 The Trustees Of The University Of Pennsylvania Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof

Similar Documents

Publication Publication Date Title
JP2025108645A5 (enExample)
JP2023153423A5 (enExample)
Dupuy et al. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes
JP2020531465A5 (enExample)
Aurelian Herpes simplex virus type 2 vaccines: new ground for optimism?
Jean-Pierre et al. Main targets of interest for the development of a prophylactic or therapeutic Epstein-Barr virus vaccine
Alami Chentoufi et al. Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown
TW200400046A (en) Viral antigens
CA2674051A1 (en) Herpes simplex virus combined subunit vaccines and methods of use thereof
JP2004535798A (ja) ヘルペスウイルスを用いた癌処置のための組成物および方法
JP2012527486A5 (enExample)
US10125174B2 (en) Herpes simplex virus vaccine
Aurelian Herpes simplex viruses
Wachsman et al. A growth and latency compromised herpes simplex virus type 2 mutant (ICP10ΔPK) has prophylactic and therapeutic protective activity in guinea pigs
Bolhassani et al. Different spectra of therapeutic vaccine development against HPV infections
Higgins et al. Plasmid DNA—Expressed Secreted and Nonsecreted Forms of Herpes Simplex Virus Glycoprotein D2 Induce Different Types of Immune Responses
Bright et al. The efficacy of HSV-2 vaccines based on gD and gB is enhanced by the addition of ICP27
Yan et al. CCL19 and CCL28 assist herpes simplex virus 2 glycoprotein D to induce protective systemic immunity against genital viral challenge
Zhou et al. Optimized DNA vaccine enhanced by adjuvant IL28B induces protective immune responses against herpes simplex virus type 2 in mice
US20240156951A1 (en) Vaccine compositions and methods for treating hsv
JP2014534262A5 (enExample)
Devadasan et al. HPV vaccines–A game changer for preventing HPV-related cancers
Wang et al. Design and evaluation of a multi-epitope assembly peptide (MEAP) against herpes simplex virus type 2 infection in BALB/c mice
EP1790332A1 (en) Vaccine for oral administration
Ramachandran et al. Potential prophylactic and therapeutic vaccines for HSV infections